{"id":"ranibizumab-nuna","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Conjunctival hemorrhage","drugRate":"74%","severity":"common","organSystem":""},{"effect":"Eye pain","drugRate":"35%","severity":"common","organSystem":""},{"effect":"Vitreous floaters","drugRate":"27%","severity":"common","organSystem":""},{"effect":"Intraocular pressure increased","drugRate":"24%","severity":"common","organSystem":""},{"effect":"Vitreous detachment","drugRate":"21%","severity":"common","organSystem":""},{"effect":"Intraocular inflammation","drugRate":"18%","severity":"common","organSystem":""},{"effect":"Cataract","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Foreign body sensation in eyes","drugRate":"16%","severity":"common","organSystem":""},{"effect":"Eye irritation","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Lacrimation increased","drugRate":"14%","severity":"common","organSystem":""}],"contraindications":["Eye infection"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Endophthalmitis","drugRate":"0.1%","severity":"serious"},{"effect":"Rhegmatogenous retinal detachment","drugRate":"0.1%","severity":"serious"},{"effect":"Iatrogenic traumatic cataract","drugRate":"0.1%","severity":"serious"},{"effect":"Tear of retinal pigment epithelium","drugRate":"","severity":"serious"},{"effect":"Thromboembolic events","drugRate":"","severity":"serious"}]},"status":"approved","trials":[],"aliases":[],"company":"SAMSUNG BIOEPIS CO LTD","patents":[],"pricing":[],"allNames":"byooviz","offLabel":[],"timeline":[],"brandName":"BYOOVIZ","ecosystem":[],"mechanism":{"target":"Vascular endothelial growth factor A","novelty":"","modality":"Small Molecule","drugClass":"","explanation":"","oneSentence":""},"commercial":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://www.fda.gov/drugs","name":"FDA Drugs@FDA","fields":["phase","status","brandName","company"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"RANIBIZUMAB-NUNA","indications":{"approved":[{"name":"Age related macular degeneration","diseaseId":"age-related-macular-degeneration","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Branch retinal vein occlusion with macular edema","diseaseId":"branch-retinal-vein-occlusion-with-macular-edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Central retinal vein occlusion with macular edema","diseaseId":"central-retinal-vein-occlusion-with-macular-edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Choroidal retinal neovascularization","diseaseId":"choroidal-retinal-neovascularization","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diabetic retinopathy","diseaseId":"diabetic-retinopathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Exudative age-related macular degeneration","diseaseId":"exudative-age-related-macular-degeneration","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Macular edema due to diabetes mellitus","diseaseId":"macular-edema-due-to-diabetes-mellitus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Retinopathy of prematurity","diseaseId":"retinopathy-of-prematurity","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"SAMSUNG BIOEPIS CO LTD","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"INJECTION","frequency":"","formulation":""},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"companyName":"SAMSUNG BIOEPIS CO LTD","companyId":"samsung-bioepis","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"BYOOVIZ is a vascular endothelial growth factor A inhibitor, classified as an antibody drug. It targets vascular endothelial growth factor A, long form, and is used to inhibit its activity.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2021-08-18T00:00:00.000Z","mah":"Samsung Bioepis NL B.V.","brand_name_local":"Byooviz","application_number":"EMEA/H/C/005545"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-09-17T00:00:00.000Z","mah":"SAMSUNG BIOEPIS CO LTD","brand_name_local":"BYOOVIZ","application_number":"BLA761202"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":false,"score":2}}